Skip to main content
. Author manuscript; available in PMC: 2020 May 9.
Published in final edited form as: Eur Cell Mater. 2019 Nov 22;38:246–263. doi: 10.22203/eCM.v038a17

Table 1. DEX studies in animal models summarising model used, DEX dosage and duration, frequency and administration route of DEX treatment and overall observed effect.

Authors Year Animal model Arthritis model DEX dose Duration Frequency and route of administration Observed effect
Huebner et al. 2014 Rabbit Yes 0.5 mg/kg 3 weeks Once/3 d, i.a. +
Heard et al. 2015 Rabbit Yes 0.5 mg/kg 48 h-9 weeks Once, i.a. +/−
Islander et al. 2010 Mouse Yes ~ 5 mg/kg ~ 25 d Daily, i.p. +
Rauchhaus et al. 2009 Mouse Yes 0.4–4 mg/kg 7 d Once, i.v. +/−
Wang et al. 2017a Rat Yes 0.15 mg/kg 7 d Daily, oral gavage +
Malfait et al. 2009 Rat Yes 1 mg/kg or 0.001–1 mg/mL 16 h Once, oral gavage or i.v. infusion +
Ashraf et al. 2011 Rat Yes 0.1 mg/kg 24 d Daily, oral gavage +
Jaffré et al. 2003 Rat Yes 0.1 mg/kg 5–21 d Daily, i.a. +/−
Annefeld and Erne 1987 Rat No 3 mg/kg 3 weeks 1/week, i.m.
Podbielski and Raiss 1985 Rat No 3.3 mg/kg 3–5 weeks 1/week, i.m.
Glade et al. 1983 Horse No 0.005 mg/kg 3–11 months Daily, i.m.

i.a.: intra-articular injection. i.p.: intra-peritoneal injection. i.v.: intravenous injection. i.m.: intra-muscular injection. + indicates a positive effect on cartilage and/or arthritis progression, − a negative effect and +/− some positive results alongside negative side effects.